NanoString Blog

Role of the host


The IO Revolution, Part 2 of 4: The Role of the Host in the Cancer Immunity Cycle

Part one of this four-part series looked at how host, tumor, and environmental factors shape tumor-immune system interactions. In the next few blogs, we will consider how each of these…

acesano / January 12, 2017
Colored scan of T lymphocytes and a cancer cell

Miscellaneous Oncology

Presidents, Rock Stars and Companion Diagnostics: 2016 Review of Immunotherapy

President Jimmy Carter announced this spring that he no longer needed treatments for the metastatic melanoma found in his brain–after treatment with pembrolizumab (Keytruda, Merck), his physicians could no longer…

acesano / January 7, 2017
Outside of the ASH 2016 venue


ASH 2016: Subtyping in Diffuse Large B-Cell Lymphoma

NanoString at ASH 2016. We attended the annual meeting of the American Society of Hematology (ASH) in San Diego. The convention center was abuzz with scientists…

acesano / January 4, 2017
Graphic of the Cancer Immunogram


The Cancer Immunogram: A Picture of Personalized Medicine

What do we already know about tumor-immune system interactions, and how can this information be used to help guide us toward the best therapeutic choice? That is exactly the question…

acesano / December 27, 2016
Photo of the SITC 2016 entrance


SITC 2016 Recap

Looking beyond anti-PD1/PDL1 with combination therapy and gene signature testing

acesano / November 21, 2016
Illustration showing the immuno-oncology relationship


The IO Revolution, Part 1 of 4: Opportunities and Challenges

Immuno-oncology (IO) focuses on harnessing the tremendous power of the human immune system to detect and destroy cancer cells.

acesano / November 21, 2016